Skip to main content
GIPResearch.com · Patent and Technology Research

Xellia Pharmaceuticals ApS Received a Patent for Polymyxins Compositions

Xellia Pharmaceuticals ApS produces pharmaceutical products.

Save or follow this source
These actions open third-party AI services. Saving, citation, and future recall are not guaranteed.
Conceptual GIPResearch illustration for Xellia Pharmaceuticals ApS Received a Patent for Polymyxins Compositions
Research and original publication material

Xellia Pharmaceuticals ApS Received a Patent for Polymyxins Compositions — research background

Research context: This article preserves existing publication material for continuity. Technical, commercial and legal references should be checked against current primary sources before making decisions.

Xellia Pharmaceuticals ApS produces pharmaceutical products. The Company offers anti-infective products and treatments, as well as contract manufacturing, stability testing, and packaging services for dry powder filled vials. Xellia serves customers worldwide. In India, the Pharmaceutical business of Xellia Pharmaceuticals ApS is focused on mineral leaching, Polymorphs and new solid states of tiacumicin B, Glycopeptide compositions, Caspofungin composition, purifying lipopeptides, purification of Micafungin. Xellia Pharmaceuticals ApS filed patent application numbered 5751/DELNP/2015 that is titled POLYMYXINS , COMPOSITIONS AND METHODS OF USE. This patent application has been granted as Patent Number 311955. The invention covers chemical compounds. A polymyxin or a salt thereof represented by formula (I):  wherein R 1 is an aliphatic linear or branched C6-C10 acyl group, or R 5 is –CH(CH3)2, –CH2CH(CH3)2, –CH(CH3)CH2CH3, or –CH2C6H5; R 6 is –CH(CH3)2, –CH2CH(CH3)2, or –CH(CH3)CH2CH3; R 2 , R3 , R4 , R7 and R8 is (CH2)xCH2N(CH2SO3M)2; wherein x is 0 or 1; and wherein M is a monovalent cation. During patent examination, the patent examiner raised objections under Section 3(d) of the Indian Patents Act, wherein the examiner stated that the claims 1-17, 18-19 are not clear if the claimed compounds act to provide an enhancement of the known efficacy i.e., demonstrate a greater technical effect and/or differ significantly in properties w.r.t the substituents. In order to overcome this objection show that the present compounds have unexpected properties when compared with the structurally closest compounds from the prior art D1. As a response to said objection, the applicant responded by submitting revised claims. Advocate Rahul Dev is a Patent Attorney & International Business Lawyer practicing Technology, Intellectual Property & Corporate Laws. He is reachable at rd (at) patentbusinesslawyer (dot) com & @rdpatentlawyer on Twitter. Quoted in and contributed to 50+ national & international publications (Bloomberg, FirstPost, SwissInfo, Outlook Money, Yahoo News, Times of India, Economic Times, Business Standard, Quartz, Global Legal Post, International Bar Association, LawAsia, BioSpectrum Asia, Digital News Asia, e27, Leaders Speak, Entrepreneur India, VCCircle, AutoTech). Regularly invited to speak at international & national platforms (conferences, TV channels, seminars, corporate trainings, government workshops) on technology, patents, business strategy, legal developments, leadership & management.

Discuss a research question related to Xellia Pharmaceuticals ApS Received a Patent for

Describe your objective and the evidence you need. The suitability and scope of any research engagement will be confirmed individually.

Discuss a research question

Source and context: Original GIPResearch.com publication dated 2019-08-29. Existing text is retained for historical continuity. Verify time-sensitive matters using official records.

None

Featured Work & Insights